Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
Standard
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. / Larrey, Dominique; Lohse, Ansgar W.; de Ledinghen, Victor; Trepo, Christian; Gerlach, Tilman; Zarski, Jean-Pierre; Tran, Albert; Mathurin, Philippe; Thimme, Robert; Arastéh, Keikawus; Trautwein, Christian; Cerny, Andreas; Dikopoulos, Nektarios; Schuchmann, Marcus; Heim, Markus H; Gerken, Guido; Stern, Jerry O; Wu, Katherine; Abdallah, Nasri; Girlich, Birgit; Scherer, Joseph; Berger, Frank; Marquis, Martin; Kukolj, George; Böcher, Wulf; Steffgen, Jürgen.
in: J HEPATOL, Jahrgang 57, Nr. 1, 1, 2012, S. 39-46.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
AU - Larrey, Dominique
AU - Lohse, Ansgar W.
AU - de Ledinghen, Victor
AU - Trepo, Christian
AU - Gerlach, Tilman
AU - Zarski, Jean-Pierre
AU - Tran, Albert
AU - Mathurin, Philippe
AU - Thimme, Robert
AU - Arastéh, Keikawus
AU - Trautwein, Christian
AU - Cerny, Andreas
AU - Dikopoulos, Nektarios
AU - Schuchmann, Marcus
AU - Heim, Markus H
AU - Gerken, Guido
AU - Stern, Jerry O
AU - Wu, Katherine
AU - Abdallah, Nasri
AU - Girlich, Birgit
AU - Scherer, Joseph
AU - Berger, Frank
AU - Marquis, Martin
AU - Kukolj, George
AU - Böcher, Wulf
AU - Steffgen, Jürgen
PY - 2012
Y1 - 2012
N2 - BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.
AB - BI 207127 is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor in vitro.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Drug Therapy, Combination
KW - Drug Resistance, Viral
KW - Hepatitis C, Chronic/drug therapy
KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Hepacivirus/drug effects
KW - Interferon-alpha/administration & dosage/adverse effects/pharmacokinetics
KW - Polyethylene Glycols/administration & dosage/adverse effects/pharmacokinetics
KW - Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics
KW - Ribavirin/administration & dosage/adverse effects/pharmacokinetics
KW - Viral Nonstructural Proteins/antagonists & inhibitors
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Drug Therapy, Combination
KW - Drug Resistance, Viral
KW - Hepatitis C, Chronic/drug therapy
KW - Antiviral Agents/administration & dosage/adverse effects/pharmacokinetics
KW - Hepacivirus/drug effects
KW - Interferon-alpha/administration & dosage/adverse effects/pharmacokinetics
KW - Polyethylene Glycols/administration & dosage/adverse effects/pharmacokinetics
KW - Recombinant Proteins/administration & dosage/adverse effects/pharmacokinetics
KW - Ribavirin/administration & dosage/adverse effects/pharmacokinetics
KW - Viral Nonstructural Proteins/antagonists & inhibitors
M3 - SCORING: Journal article
VL - 57
SP - 39
EP - 46
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 1
M1 - 1
ER -